Skip to main content

Clinical trial IJB_2732

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

Cancers
Organ Multiple
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1/1b
Academic trial Non
Sponsor Lilly
EudraCT Identifier 2017-002693-39
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03343613
Inclusion criteria Metastatic Biopsy mandatory
Last update